Policy | Funding | Influence
Insights for changemakers on navigating government opportunities.
Bioscience Bulletin – December 5, 2025
Federal Legislative Updates Ohio Legislative Updates G2G Blog Back to All Posts G2G Highlights G2G was on Capitol Hill on Monday and Tuesday with Women’s Health Advocates (WHA) and the Breast Cancer Early…
Bioscience Bulletin – Nov 21, 2025
G2G had the privilege to be participant and organizing partner at Friday’s Empowering the Future of Biotechnology Through Trusted Science event hosted by ATCC.
Bioscience Bulletin – Nov 14, 2025
On Monday, G2G Founder & CEO, Liz Powell was among the women’s health leaders at the Department of Health & Human Services (HHS) where Secretary Kennedy and FDA Director Marty Makary, announced that hormone replacement therapy (HRT) products for perimenopause and menopause would no longer need to carry black box warnings.
Bioscience Bulletin – Nov 9, 2025
Last week was an active week for health policy! Our Founder and CEO, Liz Powell, Esq., MPH attended the Milken Institute Future of Health Summit, in Washington, D.C.. She participated in the
Bioscience Bulletin
The shutdown that began on October 1 continues with no end in sight. Most Congressional Democrats refuse to support a bill to re-open the government without an extension of the Affordable Care Act subsidies, which is supported by 78% of the public according to polling by KFF.
Updates on FY25 Budget
We wanted to provide an update on recent developments in Washington around the FY25 budget and Trump Administration actions.
What’s at Stake in the Election
Before leaving DC on September 27, Congress focused on bills that reinforce party messaging, which they believe will resonate with their base, while avoiding issues that could alienate their voters and put their candidates in contentious positions.
2nd Annual Government Biotechnology Innovation Summit
G2G attended the Second Annual Government Biotechnology Innovation Summit from September 4-5
Final TCET Rulemaking
The TCET program is focused on (1) facilitating early, predictable, and safer beneficiary access to new technologies; (2) reducing uncertainty about coverage by evaluating early the potential benefits and harms of technologies with manufacturers; and (3) encouraging evidence development if notable evidence gaps exist for coverage purposes.